MA32382B1 - DÉRIVÉS INDAZOLES à SUBSTITUTION PHÉNYL OU PYRIDINYLE - Google Patents

DÉRIVÉS INDAZOLES à SUBSTITUTION PHÉNYL OU PYRIDINYLE

Info

Publication number
MA32382B1
MA32382B1 MA33398A MA33398A MA32382B1 MA 32382 B1 MA32382 B1 MA 32382B1 MA 33398 A MA33398 A MA 33398A MA 33398 A MA33398 A MA 33398A MA 32382 B1 MA32382 B1 MA 32382B1
Authority
MA
Morocco
Prior art keywords
pyridinyl
substitution
phenyl
derivatives
indazole derivatives
Prior art date
Application number
MA33398A
Other languages
Arabic (ar)
English (en)
Inventor
Markus Berger
Jan Dahmen
Karl Edman
Thomas Hansson
Martin Hemmerling
Nafizal Hossain
Henrik Johansson
Matti Lepistö
Stinabritt Nilsson
Hartmut Rehwinkel
Original Assignee
Bayer Schering Pharma Ag
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41340347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32382(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag, Astrazeneca Ab filed Critical Bayer Schering Pharma Ag
Publication of MA32382B1 publication Critical patent/MA32382B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La présente invention concerne un composé de formule (Ia). La présente invention concerne donc des dérivés d'indazolyle, des compositions pharmaceutiques comportant de tels dérivés, des procédés de préparation de ces nouveaux dérivés et l'utilisation de ces dérivés en tant que médicaments.
MA33398A 2008-05-20 2010-12-06 DÉRIVÉS INDAZOLES à SUBSTITUTION PHÉNYL OU PYRIDINYLE MA32382B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5461608P 2008-05-20 2008-05-20
US8031208P 2008-07-14 2008-07-14
US14477609P 2009-01-15 2009-01-15
PCT/SE2009/000265 WO2009142569A1 (fr) 2008-05-20 2009-05-20 Dérivés indazoles à substitution phényl ou pyridinyle

Publications (1)

Publication Number Publication Date
MA32382B1 true MA32382B1 (fr) 2011-06-01

Family

ID=41340347

Family Applications (2)

Application Number Title Priority Date Filing Date
MA33398A MA32382B1 (fr) 2008-05-20 2010-12-06 DÉRIVÉS INDAZOLES à SUBSTITUTION PHÉNYL OU PYRIDINYLE
MA33399A MA32383B1 (fr) 2008-05-20 2010-12-06 DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA33399A MA32383B1 (fr) 2008-05-20 2010-12-06 DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE

Country Status (42)

Country Link
US (5) US8211930B2 (fr)
EP (3) EP2620435A1 (fr)
JP (3) JP2011520954A (fr)
KR (2) KR101593253B1 (fr)
CN (2) CN102112449A (fr)
AR (2) AR071856A1 (fr)
AU (2) AU2009249874B2 (fr)
BR (2) BRPI0912878B1 (fr)
CA (2) CA2724508C (fr)
CL (2) CL2009001248A1 (fr)
CO (2) CO6351783A2 (fr)
CR (2) CR11802A (fr)
CY (1) CY1117330T1 (fr)
DK (1) DK2291369T3 (fr)
DO (2) DOP2010000359A (fr)
EA (2) EA201001683A1 (fr)
EC (2) ECSP10010620A (fr)
ES (1) ES2561598T3 (fr)
HK (1) HK1154580A1 (fr)
HN (1) HN2010002478A (fr)
HR (1) HRP20160071T1 (fr)
HU (1) HUE027217T2 (fr)
IL (2) IL209122A0 (fr)
MA (2) MA32382B1 (fr)
ME (1) ME02455B (fr)
MX (2) MX2010012390A (fr)
MY (1) MY173448A (fr)
NI (1) NI201000199A (fr)
NZ (1) NZ588994A (fr)
PA (2) PA8827001A1 (fr)
PE (2) PE20091925A1 (fr)
PL (1) PL2291369T3 (fr)
PT (1) PT2291369E (fr)
RS (1) RS54700B1 (fr)
SA (1) SA109300309B1 (fr)
SI (1) SI2291369T1 (fr)
SV (2) SV2010003738A (fr)
TW (2) TW200951114A (fr)
UA (1) UA102543C2 (fr)
UY (2) UY31831A (fr)
WO (2) WO2009142569A1 (fr)
ZA (2) ZA201007919B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
CN104387382A (zh) * 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
TW200951114A (en) * 2008-05-20 2009-12-16 Astrazeneca Ab Phenyl or pyridinyl substituted indazoles derivatives
WO2010125130A1 (fr) 2009-04-30 2010-11-04 Basf Se Procédé de préparation de composés isoxazoline substitués et de leurs précurseurs
WO2011061527A1 (fr) * 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
FR2955105B1 (fr) 2010-01-11 2012-04-20 Arkema France Procede de preparation d'aminoethyl imidazolidone ou de son thiocarbonyle
US9085541B2 (en) 2010-06-23 2015-07-21 Basf Se Process for producing imine compounds for combating invertebrate pests
US9006447B2 (en) 2010-11-03 2015-04-14 Basf Se Method for preparing substituted isoxazoline compounds and their precursors 4-chloro, 4-bromo- or 4-iodobenzaldehyde oximes
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
CA2827642A1 (fr) 2011-02-18 2012-11-15 Medivation Technologies, Inc. Composes et methodes de traitement du diabete
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
PE20171110A1 (es) * 2014-09-26 2017-08-07 Astrazeneca Ab Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
WO2016124722A1 (fr) * 2015-02-06 2016-08-11 Astrazeneca Ab Procédé pour la préparation de 3-5-{[(1r,2s)-2-[(2,2-difluoropropanyl)amino]-1-(2,3-dihydro-1,4-benzodioxin-6-yl]propyl]oxy}-1h-indazol-1-yl)-n-[(3r)-tétrahydrofuran-3-yl]benzamide
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
PT3350175T (pt) * 2015-09-15 2020-02-19 Leo Pharma As Moduladores não esteróides de recetores de glucocorticóides para distribuição local de fármacos
WO2017161518A1 (fr) 2016-03-23 2017-09-28 Astrazeneca Ab Nouvelle forme physique
MX2018011117A (es) 2016-03-24 2018-11-09 Astrazeneca Ab Forma cristalina.
CN106083837B (zh) * 2016-05-27 2018-08-31 浙江普洛得邦制药有限公司 一种噁唑烷酮类抗菌药物及其中间体的制备方法
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
EP3728219B1 (fr) 2017-12-18 2022-04-13 Grünenthal GmbH Pyrrolidinamides substitués i
US20200223840A1 (en) * 2019-01-11 2020-07-16 Gruenenthal Gmbh Substituted pyrrolidine amides iii
EP3986885B1 (fr) 2019-06-19 2023-05-03 Grünenthal GmbH Pyrrolidinamides substitués iv
WO2020254552A2 (fr) 2019-06-19 2020-12-24 Grünenthal GmbH Amides de pyrrolidine substitués v
WO2021136429A1 (fr) * 2019-12-31 2021-07-08 南京明德新药研发有限公司 Composé benzopyrazole
EP4178954A1 (fr) 2020-07-09 2023-05-17 Grünenthal GmbH Pyrrolidine amines substituées et amides en tant que médiateur du récepteur de glucocortoïde
WO2023274040A1 (fr) * 2021-06-28 2023-01-05 南京明德新药研发有限公司 Forme cristalline d'un composé indazole substitué par une triazolopyridine et son procédé de préparation
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB607840A (en) 1946-02-12 1948-09-06 Bristol Aeroplane Co Ltd Improvements in or relating to means for feeding ammunition to automatic fire arms
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3514696A1 (de) 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
DE3535167A1 (de) * 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
TW224462B (fr) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
CA2114981A1 (fr) 1993-02-09 1994-08-10 Kazumi Ogata Derives de l'acide quinolonecarboxylique
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
EP0679641B1 (fr) 1993-07-26 2002-10-02 Eisai Co., Ltd. Derives de sulfamide et d'ester sulfonique presentant chacun un heterocycle tricyclique
DE69430488T2 (de) 1993-08-30 2002-12-19 Robert Bosch Corp., Waltham Gehäuse mit rezirkulationsregelung zur anwendung in axiallüfter mit zarge
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
WO1996036595A1 (fr) 1995-05-19 1996-11-21 Chiroscience Limited Phenylsulfamides disubstituees en positions 3,4 et leur utilisation therapeutique
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
TW542822B (en) 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
CN1350452A (zh) 1999-05-13 2002-05-22 盐野义制药株式会社 糖尿病的预防或治疗药
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
DE60106954T2 (de) 2000-09-11 2005-12-01 Pfizer Products Inc., Groton Resorcin-derivate
FR2815030A1 (fr) 2000-10-05 2002-04-12 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
US6838074B2 (en) * 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
CA2460594A1 (fr) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Antagonistes du recepteur de la mch
WO2003043988A1 (fr) 2001-11-22 2003-05-30 Ono Pharmaceutical Co., Ltd. Composes derives de piperidine-2-one et medicaments contenant lesdits composes comme principes actifs
US7767679B2 (en) 2002-03-13 2010-08-03 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003221706B2 (en) 2002-04-11 2008-02-28 Merck Sharp & Dohme Corp. 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
WO2003099773A1 (fr) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Inhibiteurs de ccr9 et utilisation de ceux-ci
JP2004059116A (ja) 2002-07-31 2004-02-26 Sharp Corp ディスプレイ用基板収納用トレイ及びディスプレイ用基板の取り出し機構並びにディスプレイ用基板の取り出し方法
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
US20040097574A1 (en) 2002-08-29 2004-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
CA2767153A1 (fr) 2003-02-20 2004-09-02 Encysive Pharmaceuticals Inc. Antagonistes du recepteur de l'urotensine-ii de la phenylenediamine et antagonistes du ccr-9
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP1635800A2 (fr) 2003-06-10 2006-03-22 Kalypsys, Inc. Composes carbonyle utilises comme inhibiteurs de l'histone desacetylase a des fins therapeutiques
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
KR20060101772A (ko) 2003-12-19 2006-09-26 화이자 인코포레이티드 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-ｈｓｄ-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물
JP4829506B2 (ja) 2004-02-17 2011-12-07 石原産業株式会社 チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
WO2005086904A2 (fr) 2004-03-08 2005-09-22 Amgen Inc. Modulation therapeutique de l'activite de recepteur de ppar-gamma
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
WO2006046916A1 (fr) * 2004-10-29 2006-05-04 Astrazeneca Ab Nouveaux derives de sulfonamide utilises comme modulateurs du recepteur glucocorticoide et destines au traitement de maladies inflammatoires
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
SE0402636D0 (sv) * 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
ES2414479T3 (es) 2005-04-14 2013-07-19 Glaxo Group Limited Indazoles como ligandos del receptor de glucocorticoides
RU2007148225A (ru) 2005-06-10 2009-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Глюкокортикоидные миметики, способы их получения, фармацевтические композиции и их применение
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds
GB0522880D0 (en) 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
US20090170898A1 (en) * 2006-03-31 2009-07-02 Malena Bengtsson Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor
AR060536A1 (es) * 2006-04-20 2008-06-25 Glaxo Group Ltd Agonista del receptor de glucocorticoides y composiciones farmaceuticas
GB0607840D0 (en) 2006-04-20 2006-05-31 Glaxo Group Ltd Novel compounds
EP2043646B1 (fr) 2006-07-14 2012-05-16 Eli Lilly And Company (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide en tant que MODULATEUR DU RÉCEPTEUR DES GLUCOCORTICOÏDES ET PROCÉDÉS D'UTILISATION
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
GB0620406D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
MX2009004385A (es) 2006-10-23 2009-05-22 Merck & Co Inc Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide.
EP2094692B1 (fr) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulateurs du récepteur des glucocorticoïdes et de l'activité ap-1 et/ou nf-kappab et leur utilisation
EP2099767A1 (fr) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulateurs du récepteur des glucocorticoïdes et de l'activité de ap-1 et / ou de nf- b et utilisation desdits modulateurs
US20120065173A1 (en) 2006-11-23 2012-03-15 Markus Berger Chemical compounds
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
BRPI0720131A2 (pt) 2006-12-06 2014-02-04 Boehringer Ingelheim Int Glicocorticoides miméticos, métodos para fazê-los, composições farmacêuticas e usos dos mesmos.
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (fr) 2006-12-22 2008-07-03 Astrazeneca Ab Dérivés de l'indazolyl sulfonamide pour le traitement des affections induites par les récepteurs des glucocorticoïdes
US20100048950A1 (en) 2007-04-10 2010-02-25 Boehringer Ingelheim International Gmbh Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
EP2136634A4 (fr) 2007-04-10 2011-07-06 Boehringer Ingelheim Int Substances mimétiques de glucocorticoïde, procédés de préparation de celles-ci, compositions pharmaceutiques et utilisations de celles-ci
GB0708858D0 (en) 2007-05-08 2007-06-13 Glaxo Group Ltd Novel compounds
DE102007029419A1 (de) 2007-06-26 2009-01-02 Emsland-Stärke GmbH Filamentfaserschlichtemittel und Verwendung desselben
GB0720549D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720556D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720544D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720546D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0720557D0 (en) 2007-10-19 2007-11-28 Glaxo Group Ltd Novel compounds
GB0722211D0 (en) 2007-11-12 2007-12-27 Glaxo Group Ltd Novel compounds
GB0724254D0 (en) 2007-12-12 2008-01-23 Glaxo Group Ltd Novel compounds
JP2011513313A (ja) 2008-02-26 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション 選択的グルココルチコイド受容体調節剤としてのヘキサヒドロシクロペンチル［ｆ］インダゾールカルボキサミドおよびこの誘導体
US8299048B2 (en) 2008-03-06 2012-10-30 Merck Sharp & Dohme Corp. Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators
TW200951114A (en) * 2008-05-20 2009-12-16 Astrazeneca Ab Phenyl or pyridinyl substituted indazoles derivatives

Also Published As

Publication number Publication date
US20100080786A1 (en) 2010-04-01
WO2009142569A1 (fr) 2009-11-26
AU2009249872A1 (en) 2009-11-26
EP2291369A4 (fr) 2011-05-11
EA201001682A1 (ru) 2011-06-30
CR11801A (es) 2011-02-15
EA018629B1 (ru) 2013-09-30
WO2009142571A8 (fr) 2011-02-03
AU2009249874A1 (en) 2009-11-26
AU2009249874B2 (en) 2012-08-16
CR11802A (es) 2011-01-12
PE20091925A1 (es) 2010-01-24
MX2010012390A (es) 2011-03-03
RS54700B1 (en) 2016-08-31
SV2010003737A (es) 2011-03-15
KR20110007208A (ko) 2011-01-21
ES2561598T3 (es) 2016-02-29
PT2291369E (pt) 2016-03-11
US20150080434A1 (en) 2015-03-19
US8916600B2 (en) 2014-12-23
US20170081315A1 (en) 2017-03-23
IL209121A0 (en) 2011-01-31
UA102543C2 (uk) 2013-07-25
CN102112449A (zh) 2011-06-29
JP5579704B2 (ja) 2014-08-27
TWI445705B (zh) 2014-07-21
CL2009001247A1 (es) 2010-07-23
DOP2010000357A (es) 2010-12-15
JP2011520954A (ja) 2011-07-21
ME02455B (fr) 2017-02-20
CY1117330T1 (el) 2017-04-26
NI201000199A (es) 2012-11-07
PA8827101A1 (es) 2009-12-16
US9512110B2 (en) 2016-12-06
PE20091974A1 (es) 2010-02-05
DK2291369T3 (en) 2016-02-01
SI2291369T1 (sl) 2016-02-29
KR101593253B1 (ko) 2016-02-11
MX2010012529A (es) 2011-03-29
HK1154580A1 (zh) 2012-06-29
KR20110036699A (ko) 2011-04-08
BRPI0912855A2 (pt) 2015-10-13
TW200951128A (en) 2009-12-16
ECSP10010619A (es) 2010-12-30
SV2010003738A (es) 2011-03-15
PA8827001A1 (es) 2009-12-16
EA018629B8 (ru) 2013-12-30
ZA201007918B (en) 2011-07-27
EA201001683A1 (ru) 2011-06-30
US9738632B2 (en) 2017-08-22
JP2014185188A (ja) 2014-10-02
MA32383B1 (fr) 2011-06-01
US20100087489A1 (en) 2010-04-08
EP2620435A1 (fr) 2013-07-31
HUE027217T2 (en) 2016-08-29
WO2009142571A1 (fr) 2009-11-26
NZ588994A (en) 2012-08-31
TW200951114A (en) 2009-12-16
CN102099355B (zh) 2014-11-05
MY173448A (en) 2020-01-25
EP2291369A1 (fr) 2011-03-09
ECSP10010620A (es) 2010-12-30
ZA201007919B (en) 2011-07-27
CN102099355A (zh) 2011-06-15
AR071857A1 (es) 2010-07-21
CO6331310A2 (es) 2011-10-20
CO6351783A2 (es) 2011-12-20
HN2010002478A (es) 2013-01-15
BRPI0912878A2 (pt) 2020-08-18
EP2291359A1 (fr) 2011-03-09
HRP20160071T1 (hr) 2016-02-26
PL2291369T3 (pl) 2016-04-29
UY31831A (es) 2010-01-05
DOP2010000359A (es) 2010-12-15
EP2291359A4 (fr) 2011-05-11
EP2291369B1 (fr) 2015-11-04
CL2009001248A1 (es) 2010-06-11
AR071856A1 (es) 2010-07-21
IL209122A0 (en) 2011-01-31
BRPI0912878B1 (pt) 2021-11-03
US8211930B2 (en) 2012-07-03
SA109300309B1 (ar) 2013-01-22
US20120302617A1 (en) 2012-11-29
IL209121A (en) 2015-05-31
JP2011520955A (ja) 2011-07-21
CA2724584A1 (fr) 2009-11-26
CA2724508C (fr) 2016-10-25
CA2724508A1 (fr) 2009-11-26
UY31832A (es) 2010-01-05

Similar Documents

Publication Publication Date Title
MA32382B1 (fr) DÉRIVÉS INDAZOLES à SUBSTITUTION PHÉNYL OU PYRIDINYLE
MY148634A (en) Pyridazinone derivatives
MA33768B1 (fr) Triazolopyridines
DK1951730T3 (da) Heteroalkylbundne pyrimidinderivater
MY153915A (en) Organic compounds
EA201170772A1 (ru) Органические соединения
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
TW200738627A (en) Trialkylsilyl-indoles
SG158091A1 (en) Imidazoazepinone compounds
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
MX2011008195A (es) Derivados de indol como agentes anticancer.
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
ATE514698T1 (de) Tetracyclische azapyrazinoindoline als 5-ht2- liganden
ATE474574T1 (de) Imidazoazephinonverbindungen
RS53002B (en) ANTI-CANCER UNIT AND PHARMACEUTICAL COPMOSITION CONTAINING IT
DE602007005387D1 (de) Ptors